Zomedica Corp. (ZOMDF)
OTCMKTS · Delayed Price · Currency is USD
0.1233
-0.0066 (-5.12%)
At close: Mar 20, 2026
Zomedica Revenue
In the year 2025, Zomedica had annual revenue of $32.03M with 17.39% growth. Zomedica had revenue of $10.47M in the quarter ending December 31, 2025, with 32.63% growth.
Revenue
32.03M
Revenue Growth
+17.39%
P/S Ratio
3.77
Revenue / Employee
210.72K
Employees
152
Market Cap
120.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.03M | 4.75M | 17.39% |
| Dec 31, 2024 | 27.29M | 2.10M | 8.33% |
| Dec 31, 2023 | 25.19M | 6.26M | 33.05% |
| Dec 31, 2022 | 18.93M | 14.80M | 358.02% |
| Dec 31, 2021 | 4.13M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| QHSLab | 2.61M |
| Tian'an Technology Group | 2.12M |
| PetVivo Holdings | 1.11M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| Vivos | 48.62K |
| REMSleep Holdings | 6.73K |
Zomedica News
- 1 year ago - Zomedica Corp. Announces Transition to OTCQB Venture Market - Accesswire
- 1 year ago - NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM) - Business Wire
- 1 year ago - Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET - Accesswire
- 1 year ago - Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters - Accesswire
- 1 year ago - Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis - Accesswire
- 1 year ago - Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market - Accesswire
- 1 year ago - Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone - Accesswire
- 1 year ago - Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer - Accesswire